General Information
Version
3.1.0, issued
Revision date
2024-02-19
Product name
CyStain PI OxProtect - RNase A
Substance name
Nuclease, ribo
CAS No.
9001-99-4
1.2.1 Relevant identified uses
CyStain PI OxProtect is a reagent kit for nuclei extraction and DNA staining for a variety of oxidation-sensitive plant species in order to determine genome size and ploidy level. The prepared samples can be analyzed on flow cytometers with green or blue excitation and red emission
Emergency telephone
+49 (0)551 192 40
Icons in SDS
Company Information
company name
Sysmex Partec GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
info@sysmex-partec.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H334
Hazard statements
Code
Statements
H334
May cause allergy or asthma symptoms or breathing difficulties if inhaled
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Product definition
9001-99-4 (Nuclease, ribo)
Hazard pictograms
GHS08
Signal word
Danger
Hazard statements
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Precautionary statements
P284 Wear respiratory protection. P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor.
2.3 Other hazards
PBT assessment No data available. vPvB assessment No data available.
2.1 Classification of the substance or mixture
Classification in accordance with Regulation (EC) No 1272/2008 (CLP) Resp. Sens. 1; H334 Classification information This product is assessed and classified using the methods and criteria below referred to in Article 9 of Regulation (EC) n° 1272/2008: Physical hazards: determined through assessment data based on the methods or standards referred to in part 2 of Annex I to CLP Health hazards and environmental hazards: determined through toxicological and ecotoxicological assessment data based on the methods or standards referred to in Part 3 and 4 of Annex I to CLP.
